Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.145    -0.005 (-3.33%)
Bid:
0.14
Ask:
0.15
Spread: 0.01 (7.143%)
Market Cap: £1.91m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Proposed Reorganisation and General Meeting

28 Jan 2009 11:55

RNS Number : 3845M
ValiRx PLC
28 January 2009
 



VALIRX PLC

PROPOSED REORGANISATION AND GENERAL MEETING

The Company has today announced that a General Meeting of the Company will be held at 10 a.m. on 13 February 2009 at which the Directors are proposing to effect the Proposed Reorganisation.

A circular has been dispatched to Shareholders to provide them with information on, and to outline the reasons for, the Proposed Reorganisation and to explain why the Board considers it to be in the best interests of the Company and Shareholders as a whole, and why it recommends that Shareholders vote in favour of the Special Resolution to be proposed to effect the Proposed Reorganisation.

BACKGROUND TO AND REASONS FOR THE PROPOSED REORGANISATION

In order to finance the further development of the Company's business the Directors believe that additional funds will be required. The Company will look to raise this additional capital by a placing of New Ordinary Shares following approval of the Proposed Reorganisation. 

The current market price of the Company's Existing Ordinary Shares is less than the nominal value. The Company cannot issue new shares at less than the nominal value so in order to raise additional funds, the Company needs to reorganise its share capital to reduce the nominal value of its ordinary shares.

Subject to approval by the Shareholders at the General Meeting, the Directors propose to subdivide each issued Existing Ordinary Share into one New Ordinary Share and one Deferred Share and sub-divide each of the unissued Existing Ordinary Shares into six New Ordinary Shares. Immediately following the Proposed Reorganisation, the total number of New Ordinary Shares in issue will be unchanged and each existing Shareholder will continue to hold one New Ordinary Share in place of each Existing Ordinary Share. Existing certificates representing the Existing Ordinary Shares will remain valid for the New Ordinary Shares. No share certificates will be issued for the Deferred Shares.

Following the Proposed Reorganisation, and assuming no further Existing Ordinary Shares are issued between today and the Proposed Reorganisation becoming effective, the issued share capital will comprise 58,378,365 New Ordinary Shares and 58,378,365 Deferred Shares.

DEFERRED SHARES

The Deferred Shares will have no right to vote, attend or speak at general meetings of the Company and will have no right to receive any dividend or other distribution and will have only limited rights to participate in any return of capital on a winding-up or liquidation of the Company. No application will be made to the London Stock Exchange for admission of the Deferred Shares to trading on AIM. 

RECOMMENDATION

The Directors consider the proposals described in the circular to Shareholders to be in the best interests of the Company and of Shareholders as a whole. Accordingly, the Directors unanimously recommend that Shareholders vote in favour of the Special Resolution to be proposed at the General Meeting, as they intend to do in respect of their own beneficial holdings of 12,007,910 Existing Ordinary Shares representing 20.57 per cent. of the Existing Ordinary Shares in issue.

Enquiries: 

ValiRx plc

Tel: +44 (0) 20 3008 4416

Dr. Satu Vainikka

WH Ireland Limited - NOMAD & Broker

Tel: +44 (0) 161 832 2174

David Youngman / Adrian Kirk

College Hill 

Tel: +44 (0) 20 7457 2020

Sue Charles / Adrian Duffield /Justine Lamond

valirx@collegehill.com 

DEFINITIONS

The following definitions apply throughout this announcment, unless the context otherwise requires:

"Board" or "Directors"

the board of directors of the Company

"Circular"

the circular to Shareholders of the Company

"Companies Act" or "Act"

the Companies Act 1985, as amended, and the Companies Act 2006, to the extent in force

"Company" or "ValiRx"

ValiRx plc

"Deferred Shares"

the deferred shares of 5 pence each in the capital of the Company to be created by the Special Resolution. 

"Existing Ordinary Shares"

existing ordinary shares of 6 pence each in the capital of the Company

"General Meeting"

the General Meeting of the Company to be held on 13 February 2009 at 10 a.m.

"London Stock Exchange"

London Stock Exchange plc

"New Ordinary Shares"

new ordinary shares of 1 pence each in the capital of the Company following the Proposed Reorganisation

"Proposed Reorganisation"

the sub-division and reclassification of each of the Existing Ordinary Shares in issue into one New Ordinary Share and one Deferred Share and the sub-division of each unissued Existing Ordinary Share into six New Ordinary Shares

"Shareholders"

holders of Existing Ordinary Shares

"Special Resolution"

the special resolution to be proposed at the General Meeting

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEEFFASUSEIF
Date   Source Headline
22nd Jun 20267:00 amRNSConclusion of Evaluation with University of Dundee
22nd Jun 20267:00 amRNSFinal Results & Notice of AGM
2nd Jun 20267:00 amRNSConclusion of Evaluation with Stingray
1st Jun 20267:00 amRNSValiRx Exercises Option on Evaluation Asset
27th May 20267:00 amRNSCytolytix Patent Granted
21st May 20267:00 amRNSResult of Oversubscribed WRAP Retail Offer
18th May 20267:00 amRNSWRAP Retail Offer for up to £150,000
15th May 20267:00 amRNSFundraising of up to £1,155,000
31st Mar 202610:15 amRNSChange of Registered Office
26th Mar 20267:00 amRNSValiRx Commercial Update Q1 2026
24th Mar 20267:00 amRNSValiRx and TwinEdge to present Digital Twin data
4th Mar 20267:00 amRNSDirector/PDMR Shareholding
2nd Mar 20267:00 amRNSValiRx forms ValiRx Animal Health Ltd subsidiary
19th Jan 20267:00 amRNSExercise of Warrants
9th Jan 20263:45 pmRNSReplacement: Evaluation and Transfer Agreement
9th Jan 20267:00 amRNSNew Evaluation and Material Transfer Agreement
8th Jan 20261:00 pmRNSHolding(s) in Company
5th Dec 202510:56 amRNSHolding(s) in Company
24th Nov 20253:54 pmRNSHolding(s) in Company
24th Nov 20259:30 amRNSHolding(s) in Company
20th Nov 202512:11 pmRNSResult of GM & Issue of Equity
13th Nov 20252:16 pmRNSHolding(s) in Company
10th Nov 20257:00 amRNSHolding(s) in Company
4th Nov 20255:15 pmRNSPosting of Circular and Notice of General Meeting
4th Nov 20257:00 amRNSResult of WRAP Retail Offer
30th Oct 20257:21 amRNSWRAP Retail Offer for up to £300,000
30th Oct 20257:17 amRNSFundraising of up to £1,050,000
14th Oct 20257:00 amRNSInaphaea Commercial update
29th Sep 20257:00 amRNSHalf-year Report
18th Sep 20257:00 amRNSInaphaea Commercial Update
1st Sep 20257:00 amRNSCytolytix Commercial update
26th Aug 20257:00 amRNSCommercial update
7th Aug 202510:51 amRNSValiRx Awarded Grant from Open University
5th Aug 20259:53 amRNSUpdate on Evaluation Agreement with Stingray Bio
4th Aug 20257:00 amRNSLicensing Agreement with Dominion Biotech Ltd
29th Jul 20257:00 amRNSCollaboration Agreement with Voxcell BioInnovation
30th Jun 20253:48 pmRNSResult of AGM
20th Jun 20257:00 amRNSAmbrose Exercise Option on VAL401
9th Jun 202510:57 amRNSValiRx Investor Webinar
6th Jun 202510:54 amRNSHolding(s) in Company
6th Jun 20257:00 amRNSFinal Results & Notice of AGM
3rd Jun 20257:00 amRNSNew Evaluation and Material Transfer Agreement
20th May 20251:25 pmRNSHolding(s) in Company
12th May 20257:00 amRNSInaphaea Deal Extension With Dominion
30th Apr 20257:00 amRNSCommercial Update
3rd Apr 20257:00 amRNSTermination of Letter of Intent with TheoremRx
27th Mar 20257:00 amRNSDirectorate Changes and new Advisory Board
21st Mar 202511:07 amRNSDirector Disclosure Update
24th Feb 20257:00 amRNSConclusion of Evaluation Project
3rd Feb 20257:00 amRNSInaphaea Evaluation and Commercial Use Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.